Immuno-oncology therapy developer Lava Therapeutics has filed for a $100m IPO, having been set up in 2016 to exploit Amsterdam University Medical Centers research.
Lava Therapeutics, a Netherlands-based cancer immunotherapy developer based on research at Amsterdam University Medical Centers, has filed for a $100m initial public offering on the Nasdaq Global Market.
Founded in 2016, Lava is developing bispecific antibody-based treatments intended to treat cancer by activating a subset of T cells known as the Vg9Vd2 cells, which can naturally separate tumour cells and healthy cells, and engaging them to kill cancer cells.
The company’s technology is based on research by Hans van der Vliet at the Amsterdam University Medical Centers, the university hospital affiliate of Vrije Universiteit Amsterdam and University of Amsterdam.
The IPO proceeds will fund development of a drug candidate called LAVA-051 for chronic lymphocytic leukaemia, multiple myeloma and acute myeloid leukaemia, and a second candidate, LAVA-206×207, targeting metastatic castration-resistant prostate cancer.
Lava secured $1.2m in series A funding from founding investors drug development services provider…
